Study: NCT01018381

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEIT
Description: For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEIT
Description: For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOCE
Description: For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOCE
Description: For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOCE plus PEIT
Description: A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOCE plus PEIT
Description: A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOCE plus RFA
Description: For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOCE plus RFA
Description: For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MGN-3
Description: For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.